Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial
Guardado en:
Autores principales: | Andreas Kjær, Peter Rossing, Emilie H Zobel, Asger Wretlind, Rasmus S Ripa, Viktor Rotbain Curovic, Bernt J von Scholten, Tommi Suvitaival, Tine W Hansen, Cristina Legido-Quigley |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/cccfc22306d64967a2e1646bd7183cb0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial
por: Jacob K. Jensen, et al.
Publicado: (2021) -
Effect of liraglutide on expression of inflammatory genes in type 2 diabetes
por: Emilie H. Zobel, et al.
Publicado: (2021) -
The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes
por: Suvanjaa Sivalingam, et al.
Publicado: (2021) -
Author Correction: Intravital imaging of islet Ca2+ dynamics reveals enhanced β cell connectivity after bariatric surgery in mice
por: Elina Akalestou, et al.
Publicado: (2021) -
Ceramide Remodeling and Risk of Cardiovascular Events and Mortality
por: Linda R. Peterson, et al.
Publicado: (2018)